Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12751050 | 1.00 | PRCP (0.39) | PRCPNPC1L3MBTL1POLLHTR2A | |
| SCHEMBL10560526 | 0.89 | PRCP (0.41) | PRCPNPC1L3MBTL1HTR2AKDM4E | |
| SCHEMBL25674494 | 0.83 | PRCP (0.37) | PRCPNPC1L3MBTL1HTR2AKDM4E | |
| SCHEMBL20982235 | 0.83 | PRCP (0.37) | PRCPNPC1L3MBTL1HTR2AKDM4E | |
| SCHEMBL24819930 | 0.83 | PRCP (0.37) | PRCPNPC1L3MBTL1HTR2AKDM4E | |
| SCHEMBL24819937 | 0.83 | PRCP (0.37) | PRCPNPC1L3MBTL1HTR2AKDM4E | |
| SCHEMBL25674496 | 0.83 | PRCP (0.37) | PRCPNPC1L3MBTL1HTR2AKDM4E | |
| SCHEMBL14592022 | 0.82 | MEN1 (0.41) | POLLCYP2D6MEN1RECQLKMT2A | |
| SCHEMBL30290975 | 0.82 | MEN1 (0.41) | POLLCYP2D6MEN1RECQLKMT2A | |
| SCHEMBL5206019 | 0.82 | MEN1 (0.41) | POLLCYP2D6MEN1RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919490-B2 | 6-substituted 2-(benzimidazolyl)purine or purinones and 6-substituted 2-(imidazolo[4,5-c]pyridinyl)purine or purinones; Jak3 tyrosine kinase inhibitors; autoimmune and mast cell-mediated diseases, transplant rejection; antiinflammatory agents | WYETH LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7915268-B2 | And 8-substituted 2-(imidazolo[4,5-c]pyridinyl)purines; Janus kinase 3 inhibitors; autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7902187-B2 | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression | WYETH LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090069289-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080214580-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, KIT, ADORA2A | PRCP 1512/4885NPC1 1527/4885L3MBTL1 2966/4885 |
| US-20090069289-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | P2RY6, P2RY1, P2RX6 | PRCP 1752/4885NPC1 2782/4885L3MBTL1 4283/4885 |
| US-20080214580-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | P2RY6, P2RY1, P2RX6 | PRCP 1752/4885NPC1 2782/4885L3MBTL1 4283/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | PRCP 641/4885NPC1 1983/4885L3MBTL1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.